Join
Live feed
·
PRReleasevia Quantisnow
Keros Therapeutics Inc. logo

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

ByQuantisnow·Wall Street's wire, on your screen.
KROS· Keros Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KROS (Keros Therapeutics Inc.) and more on Quantisnow.